DexCom (DXCM) Downgraded by BidaskClub

BidaskClub downgraded shares of DexCom (NASDAQ:DXCM) from a strong-buy rating to a buy rating in a research report released on Thursday.

DXCM has been the subject of several other research reports. BMO Capital Markets reissued an outperform rating and set a $62.00 price objective (down previously from $90.00) on shares of DexCom in a research report on Thursday, September 28th. Raymond James Financial downgraded shares of DexCom from an outperform rating to a mkt perform rating in a research report on Friday, September 29th. Canaccord Genuity reissued a buy rating and set a $69.00 price objective (down previously from $90.00) on shares of DexCom in a research report on Thursday, September 28th. TheStreet downgraded shares of DexCom from a c- rating to a d+ rating in a research report on Wednesday, October 25th. Finally, Stephens reissued a buy rating and set a $70.00 price objective (down previously from $83.00) on shares of DexCom in a research report on Thursday, September 28th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have issued a buy rating to the stock. The company has an average rating of Buy and an average price target of $68.50.

Shares of DexCom (DXCM) opened at $56.05 on Thursday. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84. DexCom has a 12-month low of $42.62 and a 12-month high of $86.32. The stock has a market cap of $4,870.91, a price-to-earnings ratio of -98.33 and a beta of 0.31.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.11. DexCom had a negative net margin of 7.21% and a negative return on equity of 20.44%. research analysts expect that DexCom will post -0.65 EPS for the current fiscal year.

In other news, insider Terrance H. Gregg sold 10,000 shares of DexCom stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $56.86, for a total value of $568,600.00. Following the completion of the transaction, the insider now owns 484,559 shares of the company’s stock, valued at approximately $27,552,024.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Andrew K. Balo sold 3,245 shares of DexCom stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $61.23, for a total transaction of $198,691.35. The disclosure for this sale can be found here. In the last ninety days, insiders sold 46,505 shares of company stock valued at $2,653,896. 1.70% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company grew its position in shares of DexCom by 12.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,254 shares of the medical device company’s stock valued at $238,000 after acquiring an additional 354 shares during the period. Advisor Group Inc. grew its position in shares of DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after acquiring an additional 837 shares during the period. Dimensional Fund Advisors LP grew its position in shares of DexCom by 0.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 127,769 shares of the medical device company’s stock valued at $6,247,000 after acquiring an additional 1,095 shares during the period. Stifel Financial Corp grew its position in shares of DexCom by 15.2% in the 3rd quarter. Stifel Financial Corp now owns 8,567 shares of the medical device company’s stock valued at $422,000 after acquiring an additional 1,129 shares during the period. Finally, OLD National Bancorp IN grew its position in shares of DexCom by 13.2% in the 3rd quarter. OLD National Bancorp IN now owns 9,966 shares of the medical device company’s stock valued at $488,000 after acquiring an additional 1,163 shares during the period.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by BBNS and is the sole property of of BBNS. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://baseballnewssource.com/markets/dexcom-dxcm-downgraded-by-bidaskclub/1850812.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Red Sox: J.D. Martinez Continues His Physical at Spring Training Facility
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish


Leave a Reply

 
© 2006-2018 BBNS.